doi: 10.1161/01.RES.0000258492.96097.47
© 2007 American Heart Association, Inc.
Reviews |
Mechanisms of Vascular Smooth Muscle Cell Migration
From the Department of Pharmacology, University of Nevada School of Medicine, Reno.
Correspondence to William T. Gerthoffer, Department of Pharmacology, University of Nevada School of Medicine, Reno, NV 89557. E-mail wtg{at}med.unr.edu
This Review is part of a thematic series on Migration of Vascular Cells, which includes the following articles:
Mechanisms of Vascular Smooth Muscle Cell Migration
Endothelial Cell Migration During Angiogenesis
Leukocyte Migration in the Vascular Wall
Molecular Mechanisms of Endothelial Cell Migration
Endothelial Migration in Vascular Development
Kathy K. Griendling Editor
 |
Abstract |
|---|
 Top Abstract IntroductionMethods for Measuring Cell...Mechanisms of Cell MigrationFuture Directions and SummaryReferences |
|---|
Smooth muscle cell migration occurs during vascular development, in response to vascular injury, and during atherogenesis. Many proximal signals and signal transduction pathways activated during migration have been identified, as well as components of the cellular machinery that affect cell movement. In this review, a summary of promigratory and antimigratory molecules belonging to diverse chemical and functional families is presented, along with a summary of key signaling events mediating migration. Extracellular molecules that modulate migration include small biogenic amines, peptide growth factors, cytokines, extracellular matrix components, and drugs used in cardiovascular medicine. Promigratory stimuli activate signal transduction cascades that trigger remodeling of the cytoskeleton, change the adhesiveness of the cell to the matrix, and activate motor proteins. This review focuses on the signaling pathways and effector proteins regulated by promigratory and antimigratory molecules. Prominent pathways include phosphatidylinositol 3-kinases, calcium-dependent protein kinases, Rho-activated protein kinase, p21-activated protein kinases, LIM kinase, and mitogen-activated protein kinases. Important downstream targets include myosin II motors, actin capping and severing proteins, formins, profilin, cofilin, and the actin-related protein-2/3 complex. Actin filament remodeling, focal contact remodeling, and molecular motors are coordinated to cause cells to migrate along gradients of chemical cues, matrix adhesiveness, or matrix stiffness. The result is recruitment of cells to areas where the vessel wall is being remodeled. Vessel wall remodeling can be antagonized by common cardiovascular drugs that act in part by inhibiting vascular smooth muscle cell migration. Several therapeutically important drugs act by inhibiting cell cycle progression, which may reduce the population of migrating cells.
Key Words: actin • cytoskeletal dynamics • growth factors • signal transduction • vascular smooth muscle cells
|
Introduction |
|---|
|
TopAbstractIntroductionMethods for Measuring Cell...Mechanisms of Cell MigrationFuture Directions and SummaryReferences |
|---|
Smooth muscle cell migration occurs during vascular development, in response to vascular injury, and during atherogenesis. During atherogenesis, vascular smooth muscle (VSM) cells migrate to populate the intima, either from the media1 or from the circulation via migration of CD34+ hematopoietic progenitor cells, giving rise to smooth muscle progenitor cells.2 Vascular injury occurs clinically after angioplasty, vascular stent implantation, or organ transplantation. In animal models of vascular injury, intimal and medial thickening is thought to be attributable to VSM proliferation as well as migration from media to intima.3–5 During vascular development, platelet-derived growth factor (PDGF) stimulates pericyte migration or migration of other smooth muscle precursors, which is necessary for correct vessel wall formation.6 Mice lacking PDGF or PDGF receptors fail to develop normal blood vessels. Normal vessel formation occurs by formation of an endothelial cell tube followed by migration of pericytes or smooth muscle progenitor cells that differentiate to smooth muscles of the media. The hypothesized role of cell migration as a necessary process in vessel wall remodeling has stimulated strong interest in cellular events and molecular mechanisms of VSM cell migration. This review summarizes current views of basic mechanisms of cell migration and reviews studies of VSM cells that identify important proximal signals, signaling pathways, and effector proteins. Because of the scope of the literature, many interesting studies could not be included. The reader is referred to earlier reviews by Schwartz and colleagues7 and Abedi and Zachary8 for summaries of the earliest studies of VSM cell migration.
Cell migration in vivo or in vitro begins with stimulation of cell surface receptors that transduce the external signal to a series of coordinated remodeling events that alter the structure of the cytoskeleton (Figure 1). Early signaling events trigger actin polymerization, which causes protrusion of the leading edge of the cell toward a chemotactic stimulus or along a path of varying adhesiveness within the extracellular matrix (Figure 1A). New focal contacts form just behind the leading edge to increase adhesion of the cell membrane to the matrix (Figure 1B). Actomyosin motor assemblies in the cell body provide contraction that, along with cytoskeletal remodeling and detachment of focal contacts at the trailing edge, propels the cell toward the stimulus. All organelles of the cell are carried along with the remodeling cytoskeleton, possibly by adaptor and motor proteins that tether them to the cytoskeleton. Motile cells can be stimulated to undergo a generalized, randomly oriented increase in motility independent of a concentration gradient (chemokinesis) as well as a vectorial flow of the cell up or down a chemical concentration gradient (chemotaxis), or along a path of varying adhesiveness in the extracellular matrix (haptotaxis). Major goals of studies of vascular smooth muscle migration include defining the proximal signals and signal transduction pathways activated as well as defining the components of the cellular machinery that affect cell movement. These studies are part of a large effort focused on mechanisms of migration of leukocytes, fibroblasts, and the amoeboid form of Dictyostelium discoideum. For more detailed analysis of mechanisms of cell migration in nonmuscle cells, the reader is referred to the Cell Migration Consortium web site (http://www.cellmigration.org) and several excellent reviews by members of the consortium.9–11
|
|
Methods for Measuring Cell Migration |
|---|
|
TopAbstractIntroductionMethods for Measuring Cell...Mechanisms of Cell MigrationFuture Directions and SummaryReferences |
|---|
A variety of in vivo and in vitro approaches are used to define basic mechanisms of cellular migration. Most studies use either microscopic methods to record changes in cell position and shape or a modification of the Boyden chamber to assay movement of cells through a porous membrane. Immunohistochemical studies of vessels from atherosclerotic humans and animal models of vessel injury report a snapshot of smooth muscle cells in the media and intima. In diseased or injured tissues, there are more cells in the intima, attributable in part to cell migration.12 Specific aspects of cell behavior during migration in culture are imaged by phase contrast or fluorescence microscopy and analyzed with image analysis software. Changes in cell shape and position are typically induced in a "wounding" assay, in which part of a monolayer of cells is scraped off of the culture plate and the movement of remaining cells is monitored as the "wound" is refilled with cells. Chemoattractants can be added to the culture dish and chemokinetic effects monitored. A stable gradient of attractant is usually not achieved in this protocol unless the agent is incorporated into agarose gel or some other slow-release formulation.13 High-throughput wound closure assays have been developed for screening large numbers of treatments.14,15 One interesting use of this technology was the identification of a novel Rho-activated protein kinase (ROCK) inhibitor, Rockout, by screening a library of small molecules.14
The Boyden chamber assay is a popular alternate approach to wounding assays. In the Boyden chamber assay, cultured smooth muscle cells are plated on the top surface of a porous membrane (8- to 10-µm pores). The cells migrate to the bottom surface and are stained and counted. Chemokinetic and chemotactic effects of a treatment can be distinguished by "checkerboard" analysis.16 The simplest approach to counting cells on the membrane is to fix and stain the cells to visualize the nucleus. An alternate approach is to extract stain and measure absorbance of the extract.17 Nuclei can also be visualized with fluorescent DNA stains and counted by fluorescence microscopy, or cells detached from the bottom of the membrane and DNA can be detected with a fluorometer or fluorescence plate reader. Results are typically reported as fold change in migration relative to unstimulated cells or as number of cells migrating per microscope field or filter surface area. Boyden chamber assays measure the response of a population of cells to a given treatment or treatments.
In the Boyden chamber assay, the chemotactic gradient diminishes in time as cells migrate through the membrane and onto the bottom surface of the chamber. The method is sensitive and useful for rapidly testing multiple treatments that might alter migration. However, the Boyden chamber is not useful for direct observations of cell shape and position needed for investigating detailed mechanisms of migration. Depending on the design of the experiment, Boyden chamber assays may not distinguish between treatment effects on cell attachment, cell spreading, or cell migration. A Dunn chemotaxis chamber is a modification of a Zigmond chamber that generates a relatively long-lasting gradient and allows imaging of migrating cells.18,19 A long-lived concentration gradient is required to visualize the individual cell trajectories and migration velocities of a slow-moving cell, such as a smooth muscle cell. The Dunn chamber offers a significant advantage in that subtle changes in cell shape and the direction of the motion can be visualized during the experiment.19 A combination of approaches is required to define accurately the effects of promigratory and antimigratory chemicals on cell populations, on individual cell behaviors, and on subcellular structures mediating cell movement.
|
Mechanisms of Cell Migration |
|---|
|
TopAbstractIntroductionMethods for Measuring Cell...Mechanisms of Cell MigrationFuture Directions and SummaryReferences |
|---|
Proximal Signals and Initial Transduction Steps
A common goal of studies of VSM cell migration is to define the environmental cues that promote or inhibit motility. There are many promigratory and antimigratory molecules belonging to diverse chemical and functional families, including small biogenic amines, peptide growth factors, cytokines, and extracellular matrix components. Physical factors including blood flow, sheer stress, and matrix stiffness can also influence VSM cell migration.20–22 Peptide growth factors have been studied in some detail since reports in the 1980s and early 1990s indicating that PDGF is a potent, efficacious promigratory stimulus in vivo following vascular injury.23–25 Later studies of PDGF receptor knockout mice suggested that an important role of PDGF was to activate smooth muscle progenitor cells to migrate and form blood vessels.6 Interestingly, the PDGF-AA isoform is antimigratory,27 suggesting the net effect of PDGF in vivo may depend on integration of both short-term promigratory signaling by the BB isoform and antimigratory signaling by the AA isoform. In addition to short-term signaling, PDGF induces longer term sequential activation of other growth factor and cytokine signaling pathways.28 PDGF acts indirectly to induce synthesis of epidermal growth factor and fibroblast growth factor-2, both of which enhance cell migration.29 This is only one example of the well-documented ability of growth factors and cytokines to stimulate their own synthesis by smooth muscles, as well as synthesis of other growth factors and cytokines.30,31 Therefore, both direct and indirect effects of signaling proteins on VSM migration are very likely to occur in vivo during a response to injury or inflammation.
Although PDGF and other signaling proteins controlling VSM migration are soluble, other important proximal signals are presented as part of the extracellular matrix. Early studies by Schwartz and colleagues identified osteopontin as an important matrix component that promotes VSM migration.32 Osteopontin is a matrix glycoprotein containing an RGD (Arg, Gly, Asp) motif in the N-terminal domain that ligates CD44 and several integrins, including 
vß3 integrins, in a variety of cell types.33 During atherogenesis or following vascular injury, osteopontin expression increases and is thought to enhance VSM migration via vß3 integrin signaling.34–36 Similar promigratory effects have been reported for each of the major constituents of the extracellular matrix of the vessel wall, including collagens I and IV and laminin37 (see Table 1). Integrin ligation is necessary for VSM adhesion to the matrix, and it triggers promigratory intracellular signaling cascades from the "outside in." Details of key signaling cascades are described in more detail below. Integrin activation from "inside out" also occurs by virtue of soluble signals promoting protein and inositol phosphorylation events that regulate formation of nascent focal contacts (see Figure 1B). One important example is activation of the actin-binding protein talin, which alters the cytoplasmic domains of integrins to increase cell adhesiveness.38,39 As in other motile mammalian cells, VSM cell migration depends on integration of both soluble signals acting from the outside in and on changes in matrix attachment via activation of integrins from the inside out.
|
In addition to having promigratory features, the extracellular matrix can have antimigratory effects. In the normal, uninjured vessel wall, VSM cells are nonmigratory because there is little stimulus to migrate, they are not proliferating, and because the matrix is highly adhesive. Focal adhesions are presumably of the fibrillar type, which are large and relatively stable. In the absence of significant matrix metalloproteinase activity, contractile smooth muscle cells remain spindle shaped and firmly adherent to the matrix. Heparin in the matrix may also strongly inhibit cell motility,40,41 as do tissue inhibitors of metalloproteinases (TIMPs).42,43 Whether VSM cells migrate in vivo and in what direction is likely controlled by promigratory stimuli such as osteopontin balanced by antimigratory influences such as stable focal adhesions, TIMPs, and heparin.
The identity of soluble signals and matrix components that modify vascular smooth muscle migration has been a topic of active research for nearly 20 years, resulting in a voluminous literature. Table 1 summarizes examples of growth factors, cytokines, matrix components, and other molecules that enhance cell migration in vitro. The table is an incomplete list that focuses on extracellular signaling molecules important in normal cardiovascular function, vascular development, or vascular pathology. Table 2 shows a partial list of inhibitory molecules that are either endogenous molecules that regulate cardiovascular function or agents that contribute to vascular pathology, or are cardiovascular drugs. Many of the agents listed are implicated to some extent as paracrine or autocrine signals released in response to injury. Whether these agents all have important effects in vivo is an open question. In most cases, relevant in vivo studies of mouse models in which the signaling protein or its receptor is knocked out are either lacking or minimally described.
|
Cytoskeletal Proteins and the Physics of Cell Motility
The promigratory agents in Table 1 activate signal transduction cascades that trigger remodeling of the cytoskeleton, change the adhesiveness of the cell to the matrix, and activate motor proteins (Figure 1). To migrate, VSM cells need to extend lamellipodia toward the stimulus via actin polymerization, detach the trailing edge by degrading focal contacts, and generate force by myosin II in the body of the cell to propel the cell forward. Actin polymerization is coordinated by a large number of actin-binding proteins illustrated in Figure 1A. These proteins are regulated by Ca2+, phosphatidylinositol 4,5-bisphosphate (PIP2), small G proteins, and signaling cascades described below. For example, activation of the ß isoform of PDGF receptor (PDGFR-ß) is coupled via phosphatidylinositol 3-kinase (PI3K) and phospholipase C
to changes in myoplasmic calcium, hydrolysis of PIP2, and activation of mitogen-activated protein kinases (MAPK).44 Nucleation of new filaments is initiated by the actin-related protein 2/3 (ARP2/3) complex binding to the minus end and removal at the plus end of capping proteins that are sensitive to PIP2. Extension of new actin filaments is enhanced by formins (mDia1 and mDia2), which act on the plus end in concert with profilin. The formin mDia1 is activated by RhoA, and mDia2 is activated by Cdc42. Profilin liberated from membrane phospholipid binding sites increases nucleotide exchange on G-actin monomers and enhances actin polymerization. Filament branching is promoted by Rac and Cdc42 activation of WASP family verprolin–homologous protein (WAVE) complex and Wiskott–Aldrich syndrome protein (WASP), respectively. WAVE and WASP proteins each activate proteins of the actin-related protein 2/3 complex to increase nucleation and branching. Actin-filament severing by gelsolin is promoted by Ca2+, and nucleation is favored by PIP2 releasing gelsolin from plus ends of F-actin. Actin depolymerization is promoted at the minus end by cofilin, which serves to limit the length of filaments and to cause turnover of existing filaments. These processes are thought to produce sufficient force to extend the leading edge of the cell toward the stimulus.45,46
Transient focal contacts between the cell membrane and extracellular matrix are necessary for migration to proceed beyond the initial stages of actin polymerization and lamellipodia extension (Figure 1B). Nascent focal contacts at the leading edge provide adhesion of the lamellipodia to the substrate and provide traction for propulsion of the cell over or through the extracellular matrix. Degradation of mature focal contacts at the trailing edge is necessary for the cell to release from the matrix and move forward. The composition of focal contacts and mechanisms of initiation, maturation, and degradation have been extensively studied in nonmuscle cells.10,47,48 The major components of focal contacts have been described in migrating VSM cells including focal adhesion kinase (FAK),49 vinculin,50 paxillin,51,52 tensin,53 p130cas,52 and Src.54 Focal adhesion kinase is a critical regulator of cell migration that is upregulated following intimal hyperplasia.55 Formation and degradation of focal contacts is intimately associated with signal transduction occurring during migration. Multiple signaling kinases associate with focal contacts, including Src family members, FAK, phosphoinositide-dependent kinase 1, MAPKs, and PI3K. Phosphorylation of focal contact components including FAK, paxillin, and tensin occurs during VSM migration,51,53,56 as does proteolysis of focal contact proteins by metalloproteinases57,58 and calpain.59
The exact nature of spatial and temporal regulation of proteins in nascent focal contacts in VSM is mostly undefined. It is also not entirely clear to what extent signaling promotes assembly of proteins in parallel or in series. In nonmuscle motile cells, integrin clustering recruits tensin and many signaling components, including small G proteins, PAK, extracellular signal-regulated kinase (ERK), and FAK.60,61 Integrin ligation plus aggregation stimulates addition of structural proteins, including vinculin and -actinin. Tyrosine phosphorylation by FAK and Src family tyrosine kinases is necessary for proper assembly, as is filamentous actin. The assembly process is regulated and sequential with protein components entering individually or in small preformed complexes.61 A good example of sequential addition of structural proteins is that a paxillin–green fluorescenct protein fusion protein has been observed to appear in focal contacts before actinin–green fluorescenct protein.62 A good example of proteins entering as complex is that paxillin can join the nascent focal contact along with GIT1 (G-protein receptor kinase–interacting protein), PAK, and PAK-interacting exchange factor (PIX).63 Formation of nascent focal contacts containing adaptor proteins talin, vinculin, paxillin, and -actinin requires 4 events: integrin ligation, integrin clustering, phosphorylation of several components by tyrosine kinases, and an intact cortical F-actin meshwork.60 The critical features of focal contacts at the leading edge are the ability to form rapidly, persist long enough to transmit traction force to the matrix and then slide toward the center of the cells and either undergo turnover or mature to stable focal contacts. At the rear of the cell larger, more stable focal contacts must disassemble for the cell to move forward.
Traction forces transmitted through focal contacts to the matrix are generated by activation of myosin II motors via Ca2+ activation of myosin light chain kinase (MLCK) and phosphorylation of the 20-kDa regulatory myosin light chains. Ca2+-independent activation of myosin II may also occur through activation of RhoA and ROCK. Although the basic elements of force generating mechanisms are known to exist in migrating VSM cells, the details of how cells respond to the physical nature of the matrix and how myosin motors are regulated in migrating cells compared with intact muscle remain to be defined. Recent work from Ingber and colleagues shows plating VSM cells on surfaces of differing densities of fibronectin and differing degrees of stiffness altered myosin light chain phosphorylation and traction forces.64 They also showed that inhibiting myosin ATPase with 2,3-butanedione 2-monoxime (BDM) reduced myosin light chain phosphorylation. These authors suggested that decreased adhesiveness or decreased stiffness of the matrix reduces prestress on the cytoskeleton, as does inhibition of myosin ATPase. Decreased stiffness in turn inhibited myosin phosphorylation by some undefined effect on biochemical signal transduction. These observations are consistent with a model in which myosin II in migrating cells generates traction forces on the matrix, and the matrix in turn regulates activation of myosin II depending on the stiffness of the matrix.
In addition to focal contact and actin filament remodeling, cell migration also requires remodeling of microtubules. The nucleus is reoriented during migration of fibroblasts, and the microtubule organizing center (MTOC) remains in the center of the cell (Figure 1). As cells migrate, the nucleus moves toward the rear of the cell.65 Nuclear movement is affected by Cdc42 regulation of myotonic dystrophy kinase-related Cdc42 binding kinase (MRCK). MRCK phosphorylates the 20-kDa myosin light chain, which activates actomyosin.65 Microtubules remodel actively during migration, and dynamic instability is required for VSM migration. Stabilization of microtubules with paclitaxel (Taxol) inhibits PDGF-stimulated VSM migration.66 Microtubules may also contribute to dissolution of stable focal contacts, thus allowing disengagement of the trailing edge of a migrating cell.67 Relatively few studies of VSM cell migration have linked specific signaling pathways to microtubule dynamics. Urokinase plasminogen activator has been proposed to promote migration, in part, by a pathway including PI3K, Akt, and glycogen synthase kinase 3ß (GSK3ß).68 GSK3ß might exert promigratory effects via the tumor suppressor APC (adenomatous polyposis coli), which can interact with microtubules and may ultimately affect actin polymerization via a Rac-dependent mechanism. However, direct evidence for APC interaction with microtubules and promotion of actin polymerization at the leading edge of migrating VSM cells remains to be seen.
Signaling Cascades
The actin cytoskeleton is regulated by multiple signaling pathways activated by both receptor tyrosine kinases (RTKs) and G protein–coupled receptors (GPCRs) (Figure 2). Key signaling components include trimeric G proteins, small G proteins, lipid kinases, Ca2+-dependent protein kinases, ROCK, and MAPKs (Figure 2). Any stimulus that increases myoplasmic Ca2+ concentration will probably activate MLCK and myosin II. For example, Ca2+ oscillations were observed during PDGF-stimulated cell migration,69 and MLCK inhibitors block VSM cell migration.70,71 It is also clear that many promigratory stimuli activate 1 or more pathways regulating actin polymerization, including RhoA and ROCK. Participation of other kinases will depend on the specifics of receptor signal transduction.
|
Receptor Crosstalk: Sphingosine-1 Phosphate and PDGF
Most in vitro studies of VSM cell migration use a single agent to stimulate migration. VSM cells migrating in vivo are probably exposed to multiple promigratory and antimigratory molecules simultaneously. Therefore receptor crosstalk is likely to occur and to have significant effects on migration. A good example is the interaction of sphingosine-1 phosphate (S1P) and PDGF during cell migration.72,73 As noted above, PDGFR-ß knock out causes defects in vascular development attributable to failure of VSM migration.26 The S1P1 receptor knockout mouse undergoes a similar failure of vascular development caused by inhibition of VSM migration.74 This is consistent with a promigratory effect of S1P on VSM cell migration in vitro75,76 but is inconsistent with several reports of antimigratory effects of S1P.44,77 Activation of S1P1 receptors promotes migration, whereas activation of S1P5 receptors generally antagonizes cell migration in nonmuscle cells.78 S1P and PDGF might enhance migration in vivo during development or during atherogenesis in 2 ways: (1) by enhancing synthesis of the other agent causing sequential activation of receptors44,79; and (2) by interactions of the S1P1 receptor with the PDGFß receptor.72,80 There are several potential mechanisms of receptor interaction, including transactivation of S1P receptors by PDGF81 and S1P1 receptors serving as adaptors for PDGF receptor activation of focal adhesion signaling.82 Another somewhat different mechanism has been observed in airway smooth muscle cells.80,83 PDGF receptor activation causes release of sphingosine kinase from the smooth muscle cell, which is hypothesized to produce S1P from sphingosine secreted from other cell types. S1P then activates a S1P1/PDGFR-ß complex that enhances migration. It is possible that VSM cell migration in vivo is mediated by sequential receptor activation after mediator synthesis, receptor transactivation, and/or receptor–receptor complex formation. The extent to which these mechanisms occur during VSM migration is not well defined, nor is it clear how common receptor crosstalk is between other RTKs and GPCRs in migrating VSM cells.
Small G Proteins and ROCK
The small G proteins (Ras, Rho, Rac, Cdc42) are very early elements in signaling pathways that promote cell migration. Both RTKs and GPCRs activate several small G proteins via regulation of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins. Although there are a few studies of GEFs in VSM cell migration,84,85 little is known of the details of either GEFs or GTPase-activating proteins in small G-protein function in smooth muscle.
In general, activation of small G proteins activates downstream protein kinases that phosphorylate effector proteins regulating actin, microtubule or intermediate filament function. Rho A activates ROCK1 and ROCK2 in VSM,86 and Rho kinase inhibition by C3 exoenzyme, fasudil, or Y-27632 blocks VSM cell migration.87–89 ROCK phosphorylates the myosin binding subunit of myosin light chain phosphatase, thus reducing phosphatase activity.90,91 This is a prominent mechanism of agonist-induced calcium sensitization of smooth muscle contraction that contributes significantly to cell migration as well. ROCK can also directly phosphorylate myosin light chains in vitro at Ser19,92 but this mechanism is debatable in differentiated vascular smooth muscle. In cultured 3T3 fibroblasts, ROCK directly phosphorylates myosin II located at the core of the cell but not in the periphery.93 It may be that migrating cells regulate actomyosin differently from differentiated cells and that ROCK can substitute for MLCK or act in concert with MLCK to phosphorylate myosin II during migration. In addition to effects on myosin II phosphorylation, ROCK promotes actin polymerization by activation of LIM kinase. Activation of LIM kinase will inhibit cofilin-mediated actin depolymerization favoring increased F-actin during migration.94 Although there are reports of dynamic changes in cofilin and LIM kinase expression in vascular smooth muscle,95,96 it is not known whether this mechanism is necessary for cell migration.
Activation of Rac1 has been observed during VSM migration stimulated by PDGF.97 Rac2 was recently reported to be inducible by inflammatory cytokines in VSM and to promote migration by interacting with a cytokine-inducible scaffold protein, allograft inflammatory factor-1.98 Rac1 may be under negative control by the Slit axon guidance proteins,99 which suggests a balance of positive and negative migratory factors may determine smooth muscle cell location during development in a fashion similar to the developing nervous system. Rac1 and Rac2 both activate PAKs, which are also positively modulated by reactive oxygen species, Ca2+, and protein kinase C.85,100
p21-Activated Protein Kinases
PAKs phosphorylate several substrates that regulate cell migration. Phosphorylation of LIM kinase by PAK results in phosphorylation of cofilin, which promotes actin depolymerization.101 PAK phosphorylation of MLCK inhibits myosin phosphorylation.101 In contrast, PAK has also been reported to phosphorylate myosin light chains directly, which would activate actomyosin.102 PAK phosphorylates 2 actin-binding proteins, cortactin and caldesmon. PAK phosphorylation of h-caldesmon activates muscle actomyosin, thus increasing muscle contraction.103,104 However, l-caldesmon is the predominant caldesmon isoform expressed in cultured VSM. It is phosphorylated during PDGF-induced VSM migration,105 and l-caldesmon phosphorylation is necessary for stress fiber disassembly.106 PAK also phosphorylates cortactin, which reduces its binding to actin and may reduce actin branching.107 In addition to profound effects on the actin cytoskeleton and myosin motor protein, PAK may modify microtubule and intermediate filament structure. The activity of the microtubule-destabilizing protein Op18/stathmin is inhibited by Rac1 activation of PAK, resulting in stabilization of microtubules.108 PAK also phosphorylates desmin and vimentin to enhance intermediate filament turnover.109,110 Although expression of kinase-inactive PAK inhibits smooth muscle cell migration very effectively,100,111 it is not clear which of the positive or negative effects of PAK on cytoskeletal filaments, myosin, and focal adhesions predominate during VSM migration. Nor is it clear how the diverse effects of PAK enzymatic activity and chaperone function are orchestrated to promote coordinated cell movement. Spatial and temporal control of PAK function is mediated by several adaptor proteins in nonmuscle cells, including Nck,112 PAK-interacting exchange factor,113 and paxillin kinase linker (PKL).114 It is not known whether these proteins play similar roles in migrating VSM cells.
Src Family Tyrosine Kinases
Src and PI3Ks are proximal components of signaling cascades activated by both growth factor receptors (RTKs) and GPCRs (see Figure 2). Smooth muscle cells express multiple Src family members, including Src, Fyn, Lyn, and Yes. PDGF activates Src during VSM cell migration, and inhibiting Src with drugs or anti-Src antibodies inhibits PDGF-induced VSM cell migration.54,100,115 Src activity is not necessary for cell attachment, but cell spreading and chemotaxis both depend on Src activity and PI3K activity.116 Likely downstream targets of Src include the ERK MAPK signaling cascade and focal contact proteins FAK, p130cas, and paxillin. Defining the position of Src family kinases in signaling cascades and defining the substrates important for cell migration is a challenging task because of redundancy in Src signaling. The multiple Src family members expressed in smooth muscles have similar target phosphorylation sites and, therefore, may have overlapping substrate selectivity. Furthermore, chemical Src inhibitors do not discriminate well among Src family members. The fact that single and multiple Src family knockout mice are available, and that viral vectors can be used in rescue strategies, provides an avenue for some progress, but this has not been actively pursued.
Phosphatidylinositol 3-Kinases
PI3Ks are proximal components of many signaling pathways in VSM that control diverse cellular functions, including proliferation, cell survival, and cell motility They phosphorylate phosphatidylinositol at position D3 of the inositol ring, resulting in activation of several signaling cascades implicated in VSM cell migration, including ERK and p38 MAPKs.105 PI3K has also been recently linked to remodeling of microtubules through Akt, GSK3ß, and adenomatous polyposis coli.68 Evidence for the necessity of PI3K in VSM cell migration is mixed. In some cases, chemical inhibitors wortmannin or LY294002 have modest antagonistic effect on VSM migration116,117 and, in other cases, no effect.118–120 The variability in the literature may result from the types of stimuli used and subtle differences in cells from different species and tissues. With respect to stimulus differences, one idea is that a highly efficacious stimulus such as PDGF-BB activates redundant signaling pathways, and, therefore, inhibiting only one signaling component may not inhibit cell migration very effectively.117,120 Other stimuli may activate a more limited set of signaling events that are more easily blocked by a chemical or molecular intervention. Examples of more limited stimuli might include phorbol ester activation of protein kinase C, or matrix proteins such as osteopontin that activate a subset of integrins.
Mitogen-Activated Protein Kinases
MAPK cascades are among the most common and important signaling cascades activated by both receptor and nonreceptor tyrosine kinases. Defining the role of ERK, p38 MAPK, and C-Jun N-terminal kinase (JNK) MAPK families in cell migration is facilitated by effective and relatively selective small molecule inhibitors. There are also good molecular tools used to express kinase-dead or constitutively active kinases. In early studies, PD98059 was used to inhibit MAPK/ERK1 (MEK1), the immediate upstream activator of ERKs, and to inhibit rat VSM cell migration.121 In the same study, antisense oligonucleotide against ERKs also partially inhibited PDGF-BB–induced migration.121 ERK activation is typically biphasic in response to growth factor stimulation, with early activation within minutes being required for cell migration and later ERK activity being associated with cell proliferation.122 Many of the promigratory stimuli listed in Table 1 activate ERK MAPKs in VSM. Although ERK activation has been described as a necessary event in VSM cell migration, there are also studies citing no effect of ERK inhibition, or even ERK-mediated inhibition of migration.123 This suggests that a canonical Ras/Raf/MEK/ERK signaling cascade can, and probably does, participate in VSM migration but that there is redundancy in the signaling networks that, in some experiments, compensates for ERK inhibition. Figure 2 shows examples of signaling redundancy in regulation of actin polymerization and myosin II phosphorylation. It is clear that, in the absence of ERK activity, there are still multiple pathways by which myosin II motors can be activated.
Despite an extensive use of chemical and molecular tools in correlative studies, it is not entirely clear how ERK activation promotes smooth muscle cell motility. Possible downstream substrates that might directly contribute to enhanced motility include the actin-binding protein l-caldesmon,105 MLCK,124,125 focal adhesion kinase, and calpain.126 Indirect, longer-term effects on cell migration might be exerted by regulating transcription factors that control expression of promigratory growth factors, matrix proteins, and matrix metalloproteinases.127,128
The p38 MAPK cascade has also been implicated in VSM cell migration with the use of both chemical inhibitors of p38 MAPK and gene transfer approaches. A signaling cascade comprising MAPK kinase 3 (MKK3), p38 MAPKs, MAPK activated protein kinase 2 (MK2), and heat shock protein 27 (HSP27) is necessary for migration of both smooth muscle cells129,130 and endothelial cells.131 The p38 MAPK cascade is activated by numerous promigratory stimuli, including PDGF, angiotensin II, S1P, and thrombin. Thrombin stimulates this pathway via reactive oxygen species.132 Chemical inhibitors of p38 MAPK block vascular remodeling in a rabbit injury model,133 although, interestingly, blockade of p38 MAPK did not block migration of cultured cells in this case. Inhibition of p38 MAPK also inhibits reorientation of cultured VSM in response to stretch,134 suggesting p38 MAPK and its targets are early sensors of both the chemical and mechanical milieu of the vessel wall. The effect of p38 MAPK inhibitors in vascular remodeling is likely to be a combination of effects on cell migration via inhibiting phosphorylation of heat shock protein 27 and actin remodeling as well as effects on transcription and translation of proinflammatory mediators and proteins regulating the cell cycle.
Less is known about the role of JNK MAPKs in VSM migration compared with ERK and p38 MAPKs. The chemical inhibitors of JNK family members are less selective than MEK and p38 MAPK inhibitors and therefore somewhat less useful for definitive studies of kinase action in cells. However, adenoviral overexpression of kinase-dead constructs provides some insight into the contribution of JNKs to migration. Overexpression of a kinase-dead mutants of each MAPK family partially inhibits migration induced by PDGF-BB.135 Overexpressing JNK1 also inhibits angiotensin II–induced migration.85 Protein kinase C, proline-rich tyrosine kinase-2 (PYK2), and Rho/ROCK were found to be upstream of JNK activation and cell migration, but the downstream targets of JNK are less clear. C-Jun has been reported to be necessary for PDGF-induced VSM migration,136 but how this protein affects migration is unknown. JNK can phosphorylate microtubule-associated proteins and paxillin.126 Paxillin seems like a very likely target for JNK-mediated cell migration of VSM cells. Phosphorylation of Ser178 in paxillin by JNK was shown to be necessary for focal adhesion formation and cell migration in fish keratocytes and bladder epithelial tumor cells.137 Whether this phosphorylation event occurs in VSM cells during migration is an open but interesting question.
Integrin-Linked Kinase
Integrin-linked kinase (ILK) has recently been proposed to modify several aspects of cytoskeletal and contractile protein function that could affect VSM cell migration. ILK interacts with the cytoplasmic tail of ß integrins and serves as an adaptor protein. It binds several proteins linking integrins to the actin cytoskeleton, including affixin and paxillin.138,139 It also binds PINCH, which is an adaptor linking ILK to receptor tyrosine kinases and lipid kinases, classes of signaling kinases described above that promote VSM cell migration. Production of phosphatidylinositol 3,4,5-phosphate (PIP3) by PI3K activates ILK, and dephosphorylation of PIP3 by PTEN reduces ILK activity.
The substrates and functions of ILK in VSM are not fully defined, but ILK may alter cell motility by enhancing myosin light chain phosphorylation and activating myosin II motors. ILK can inactivate myosin phosphatase,140,141 and it can phosphorylate myosin light chains directly.142 Direct evidence of a role in VSM migration is provided by overexpressing dominant negative ILK, which blocks angiotensin II–stimulated migration.143 In the same study ILK expression in mouse aorta was downregulated by statin treatment, suggesting ILK may be one of the anti-atherogenic targets effected by statins.
PTEN
PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome Ten) is a multifunctional phosphatase that acts primarily as a 3' lipid phosphatase to dephosphorylate PIP3 to PIP2. Because there are many downstream targets of PI3K and PIP3, PTEN participates in diverse processes including transcription, protein synthesis, cell cycle progression, and cell migration.144,145 Studies in nonmuscle cells suggest that one critical function of PTEN in cell migration is to allow focal adhesions at the trailing edge to disassemble as part of the process of dissociating the rear of the cell from the extracellular matrix. Focal contact disassembly may be attributable in part to dephosphorylation of PIP3 and inactivation of ILK as well as direct dephosphorylation of FAK.146,147 Cell migration might also be enhanced through activation of Rac GEFs.148 The necessity for PTEN in VSM migration is suggested by the fact that overexpressing PTEN reduces PDGF-mediated migration.149 In contrast, reduced PTEN activity in a PTEN+/–, ApoE–/– mouse model had no effect on the development of atheroma.150 Therefore, although PTEN activity is necessary for key signaling processes in smooth muscle proliferation and migration, it is not clear whether or not modulation of PTEN activity alone is sufficient to alter the development of atherosclerotic lesions.
Cardiovascular Drugs and VSM Cell Migration
Many studies of VSM cell migration conclude with suggestions that inhibiting cell migration might be useful for preventing or reducing angiogenesis or reducing the sequelae of vascular injury. This seems reasonable in principle and is probably a contributing factor in the beneficial effects of rapamycin and paclitaxel incorporated into vascular stents.151 Cell migration is sensitive to the proliferative state of VSM cells. Nonproliferating cells in culture are not migratory.152,153 Growth-arrested cells do not migrate in response to PDGF, in part, because of uncoupling of PDGF activation of Ca2+/calmodulin-dependent protein kinase II (CaMKII).154 In proliferating cultures, a very small fraction of smooth muscle cells migrate in response to PDGF. When cultured rat VSM cells were synchronized by serum withdrawal and then stimulated to migrate, most migrating cells were in the G1(b) phase of the cell cycle.155 This is consistent with observations that several drugs that block cell cycle progression also block cell migration. Rapamycin inhibits cell cycle progression at the G1-to-S transition by disrupting several critical processes including cdck2 activation and Rb phosphorylation. Rapamycin also inhibits VSM cell migration,156 in part, by upregulating expression of the cdk inhibitor p27(Kip1).157 Paclitaxel stabilizes microtubules and blocks cell cycle progression. It inhibits VSM migration66 and is effective in drug-eluting stents to prevent restenosis. The antimigratory effect of paclitaxel is probably caused by combined inhibition of cell cycle progression and inhibition of dynamic instability of microtubules. Dynamic instability is necessary for proper dissolution of focal contacts at the trailing edge of migrating cells.67 Apolipoprotein E is thought to reduce migration by inhibiting ERK MAPK activation and cyclin D1 expression, thus preventing transition from G0 to G1 of the cell cycle.158 Sabiporide, an Na/H exchanger inhibitor, also blocks the G0-to-G1 transition and inhibits human pulmonary artery VSM migration.159 Peroxisome proliferator-activated receptor (PPAR) activators have beneficial cardiovascular effects attributable, in part, to reducing migration. Troglitazone inhibits VSM migration160,161 as well as ERK MAPK activation, degradation of p27(Kip1), retinoblastoma protein phosphorylation, and cell cycle progression from G1 to S.162 In principle, any treatment that reduces cell cycle progression and proliferation should reduce the number of cells available to migrate in response to growth factors and other chemotactic stimuli.
Statins are 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors indicated for treatment of hyperlipidemias. Although inhibiting cholesterol synthesis is often the primary therapeutic goal, statins also have beneficial side effects as inhibitors of VSM proliferation, matrix protein synthesis, and cell migration.163,164 The many cardiovascular benefits of statins have led to the use of these drugs to help prevent atherosclerotic disease. An important mechanism underlying the pleiotropic effects of statins is inhibition of mevalonate synthesis and the isoprenylation reactions important in signal transduction by small G proteins.165 As seen in Figures 1 and 2
, all of the small G proteins participate in cytoskeletal and focal contact remodeling that occurs during cell migration. It is therefore not surprising that cell migration is inhibited in vitro. Reduced cell migration and proliferation in vivo probably both contribute to achieving the therapeutic goal of inhibiting vascular wall remodeling.
|
Future Directions and Summary |
|---|
|
TopAbstractIntroductionMethods for Measuring Cell...Mechanisms of Cell MigrationFuture Directions and SummaryReferences |
|---|
Migration in Three Dimensions
There are interesting similarities between the response of VSM cells to injury or inflammation and the phenotype of metastatic cancer cells. In both cases, cells respond to environmental clues by proliferating, secreting signaling molecules that are chemotactic, degrading the basement membrane by secreting matrix metalloproteinases, and invading the matrix.166–168 Most studies cited in this review are of cells migrating in 2 dimensions on very stiff substrates, such as glass or porous polycarbonate membranes. Conditions for cell migration in vivo are very different. Cells interact with the matrix on all surfaces, not just on the basal surface. The shape of the cell and the types and kinetics of focal contacts may be fundamentally different. For example, fibroblasts embedded in 3D matrices form focal contacts using a more limited set of integrins than cells on 2D matrices.169 This might result from differences in matrix stiffness that alter mechanical signaling from the matrix.22,64,170 The distribution of key signaling molecules may be quite different, and the types and rates of biochemical reactions controlling the cytoskeleton may be quite different in flat cells on a 2D matrix versus more rounded spindle-shaped VSM cells seen in 3 dimensions. This raises some interesting questions about integrin activation in migrating VSM. Do the same sets of receptor (RTKs and GPCRs), integrins, and focal contact components mediate migration during development compared with an injury response? This question might not be answered accurately in 2D cell cultures. Advances in imaging technology now allow measurement of cell shape, migration velocity, and traction forces at high spatial and temporal resolution.171 Specific candidate proteins can be visualized by expressing fluorescent fusion proteins that often cause minimal or no disruption of protein function. Visualization of dynamic changes in actin filament structure by speckle microscopy is an instructive example.172 One goal for future studies might be to incorporate fluorescent markers into key proteins and track redistribution within the cell in 3 dimensions during migration. For example, trafficking of critical signal transduction proteins could be followed by covalently pulse labeling epitope tags with fluorescent substrates.173 These approaches are substantially more complex than imaging cells in 2D space, but they may provide information highly relevant to behavior of cells in vivo.174,175
Summary
Several thousand studies of VSM cell migration have been published since pioneering work of the early 1980s showing PDGF is a potent stimulant of VSM cell migration. This extensive literature includes an impressive number of physiologically relevant extracellular signaling molecules and drugs that either stimulate or inhibit migration. VSM cell migration may occur in vivo under a number of conditions: during growth of new vessels, during atherogenesis, and following vascular injury. In all 3 conditions, signaling molecules are produced that favor migration. Chemical and molecular interventions have been described that block migration and disrupt vessel remodeling. Some of the drugs that block migration are among the mainstays of cardiovascular medicine, such as the statins. Major signaling pathways common to most mammalian cells are activated to control cytoskeletal remodeling and focal contact remodeling. Chief among these are small G proteins, Rho kinase, actin-binding proteins, and myosin II motors. The biophysical events that cause cells to migrate are not studied in as much detail in VSM cells as in other cells, such as fibroblasts, neutrophils, and the amoeboid stage of Dictyostelium discoideum. However, motile cells all share the major features of cell polarization, dynamic cytoskeletal, and focal contact remodeling at the leading and trailing edge, generation of propulsive and traction forces by myosin motors—all of which result in coordinated movement along concentration gradients of soluble chemicals or matrix components. Advances in imaging technology and vascular tissue bioengineering offer an opportunity to conduct future studies on these interesting processes in 3D cultures. These approaches may provide some additional insights highly relevant to motile behavior of VSM cells in vivo.
|
Acknowledgments |
|---|
Sources of Funding
Support was provided by National Heart, Lung and Blood Institute grant HL077726.
Disclosures
None.
|
Footnotes |
|---|
Original received October 17, 2006; revision received November 28, 2006; accepted January 9, 2007.
|
References |
|---|
|
TopAbstractIntroductionMethods for Measuring Cell...Mechanisms of Cell MigrationFuture Directions and SummaryReferences |
|---|
1. Murry CE, Gipaya CT, Bartosek T, Benditt EP, Schwartz SM. Monoclonality of smooth muscle cells in human atherosclerosis. Am J Pathol. 1997; 151: 697–705.[Abstract]
2. Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation. 2003; 108: 2070–2073.
3. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol. 1989; 14 (suppl 6): S12–S15.
4. Majesky MW, Schwartz SM. Smooth muscle diversity in arterial wound repair. Toxicol Pathol. 1990; 18: 554–559.[Medline] [Order article via Infotrieve]
5. Reidy MA. Factors controlling smooth-muscle cell proliferation. Arch Pathol Lab Med. 1992; 116: 1276–1280.[Medline] [Order article via Infotrieve]
6. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999; 126: 3047–3055.[Abstract]
7. Schwartz SM. Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest. 1997; 99: 2814–2816.[Medline] [Order article via Infotrieve]
8. Abedi H, Zachary I. Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc Res. 1995; 30: 544–556.[CrossRef][Medline] [Order article via Infotrieve]
9. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR. Cell migration: integrating signals from front to back. Science. 2003; 302: 1704–1709.
10. Vicente-Manzanares M, Webb DJ, Horwitz AR. Cell migration at a glance. J Cell Sci. 2005; 118: 4917–4919.
11. Vogel V, Sheetz M. Local force and geometry sensing regulate cell functions. Nat Rev Mol Cell Biol. 2006; 7: 265–275.[CrossRef][Medline] [Order article via Infotrieve]
12. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res. 1985; 56: 139–145.
13. DeLong SA, Moon JJ, West JL. Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. Biomaterials. 2005; 26: 3227–3234.[CrossRef][Medline] [Order article via Infotrieve]
14. Yarrow JC, Totsukawa G, Charras GT, Mitchison TJ. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem Biol. 2005; 12: 385–395.[CrossRef][Medline] [Order article via Infotrieve]
15. Kumar N, Zaman MH, Kim HD, Lauffenburger DA. A high-throughput migration assay reveals HER2-mediated cell migration arising from increased directional persistence. Biophys J. 2006; 91: L32–L34.[CrossRef][Medline] [Order article via Infotrieve]
16. Zigmond SH, Hirsch JG. Leukocyte locomotion and chemotaxis: new methods for evaluation, and demonstration of a cell-derived chemotactic factor. J Exp Med. 1973; 137: 387–410.[Abstract]
17. Grotendorst GR. Spectrophotometric assay for the quantitation of cell migration in the Boyden chamber chemotaxis assay. Methods Enzymol. 1987; 147: 144–152.[Medline] [Order article via Infotrieve]
18. Wells CM, Ridley AJ. Analysis of cell migration using the Dunn chemotaxis chamber and time-lapse microscopy. Methods Mol Biol. 2005; 294: 31–41.[Medline] [Order article via Infotrieve]
19. Zicha D, Dunn GA, Brown AF. A new direct-viewing chemotaxis chamber. J Cell Sci. 1991; 99 (pt 4): 769–775.[Abstract]
20. Ward MR, Tsao PS, Agrotis A, Dilley RJ, Jennings GL, Bobik A. Low blood flow after angioplasty augments mechanisms of restenosis: inward vessel remodeling, cell migration, and activity of genes regulating migration. Arterioscler Thromb Vasc Biol. 2001; 21: 208–213.
21. Li C, Wernig F, Leitges M, Hu Y, Xu Q. Mechanical stress-activated PKCdelta regulates smooth muscle cell migration. FASEB J. 2003; 17: 2106–2108.[Medline] [Order article via Infotrieve]
22. Peyton SR, Putnam AJ. Extracellular matrix rigidity governs smooth muscle cell motility in a biphasic fashion. J Cell Physiol. 2005; 204: 198–209.[CrossRef][Medline] [Order article via Infotrieve]
23. Grotendorst GR, Seppa HE, Kleinman HK, Martin GR. Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor. Proc Natl Acad Sci U S A. 1981; 78: 3669–3672.
24. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992; 89: 507–511.[Medline] [Order article via Infotrieve]
25. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb. 1993; 13: 1218–1226.
27. Koyama N, Morisaki N, Saito Y, Yoshida S. Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells. J Biol Chem. 1992; 267: 22806–22812.
28. Marmur JD, Poon M, Rossikhina M, Taubman MB. Induction of PDGF-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury. Circulation. 1992; 86 (suppl III): III-53–III-60.[Medline] [Order article via Infotrieve]
29. Pintucci G, Yu PJ, Saponara F, Kadian-Dodov DL, Galloway AC, Mignatti P. PDGF-BB induces vascular smooth muscle cell expression of high molecular weight FGF-2, which accumulates in the nucleus. J Cell Biochem. 2005; 95: 1292–1300.[CrossRef][Medline] [Order article via Infotrieve]
30. Casscells W. Smooth muscle cell growth factors. Prog Growth Factor Res. 1991; 3: 177–206.[CrossRef][Medline] [Order article via Infotrieve]
31. Singer CA, Salinthone S, Baker KJ, Gerthoffer WT. Synthesis of immune modulators by smooth muscles. Bioessays. 2004; 26: 646–655.[CrossRef][Medline] [Order article via Infotrieve]
32. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res. 1994; 74: 214–224.
33. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor inducing kinase: a key regulator in osteopontin-induced MAPK/IkappaB kinase dependent NF-kappaB-mediated promatrix metalloproteinase-9 activation. Glycoconj J. 2006; 23: 221–232.[CrossRef][Medline] [Order article via Infotrieve]
34. O’Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson JB, Schwartz SM, Giachelli CM. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb. 1994; 14: 1648–1656.
35. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci. 1995; 760: 109–126.[Medline] [Order article via Infotrieve]
36. Panda D, Kundu GC, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K, Mukherjee AB. Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci U S A. 1997; 94: 9308–9313.
37. Nelson PR, Yamamura S, Kent KC. Extracellular matrix proteins are potent agonists of human smooth muscle cell migration. J Vasc Surg. 1996; 24: 25–32.[CrossRef][Medline] [Order article via Infotrieve]
38. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol. 1995; 11: 549–599.[CrossRef][Medline] [Order article via Infotrieve]
39. Liddington RC, Ginsberg MH. Integrin activation takes shape. J Cell Biol. 2002; 158: 833–839.
40. Au YP, Kenagy RD, Clowes MM, Clowes AW. Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis. 1993; 23 (suppl 1): 177–182.[Medline] [Order article via Infotrieve]
41. Koyama N, Kinsella MG, Wight TN, Hedin U, Clowes AW. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. Circ Res. 1998; 83: 305–313.
42. Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res. 1996; 79: 812–820.
43. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther. 1998; 9: 867–877.[Medline] [Order article via Infotrieve]
44. Bornfeldt KE, Raines EW, Graves LM, Skinner MP, Krebs EG, Ross R. Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann N Y Acad Sci. 1995; 766: 416–430.[Medline] [Order article via Infotrieve]
45. Mogilner A, Oster G. Polymer motors: pushing out the front and pulling up the back. Curr Biol. 2003; 13: R721–R733.[CrossRef][Medline] [Order article via Infotrieve]
46. Prass M, Jacobson K, Mogilner A, Radmacher M. Direct measurement of the lamellipodial protrusive force in a migrating cell. J Cell Biol. 2006; 174: 767–772.
47. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci. 2003; 116: 1409–1416.
48. Zaidel-Bar R, Cohen M, Addadi L, Geiger B. Hierarchical assembly of cell-matrix adhesion complexes. Biochem Soc Trans. 2004; 32: 416–420.[CrossRef][Medline] [Order article via Infotrieve]
49. Hauck CR, Hsia DA, Schlaepfer DD. Focal adhesion kinase facilitates platelet-derived growth factor-BB-stimulated ERK2 activation required for chemotaxis migration of vascular smooth muscle cells. J Biol Chem. 2000; 275: 41092–41099.
50. Okada SS, Tomaszewski JE, Barnathan ES. Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp Cell Res. 1995; 217: 180–187.[CrossRef][Medline] [Order article via Infotrieve]
51. Abedi H, Dawes KE, Zachary I. Differential effects of platelet-derived growth factor BB on p125 focal adhesion kinase and paxillin tyrosine phosphorylation and on cell migration in rabbit aortic vascular smooth muscle cells and Swiss 3T3 fibroblasts. J Biol Chem. 1995; 270: 11367–11376.
52. Riedy MC, Brown MC, Molloy CJ, Turner CE. Activin A and TGF-beta stimulate phosphorylation of focal adhesion proteins and cytoskeletal reorganization in rat aortic smooth muscle cells. Exp Cell Res. 1999; 251: 194–202.[CrossRef][Medline] [Order article via Infotrieve]
53. Jiang B, Yamamura S, Nelson PR, Mureebe L, Kent KC. Differential effects of platelet-derived growth factor isotypes on human smooth muscle cell proliferation and migration are mediated by distinct signaling pathways. Surgery. 1996; 120: 427–431.[CrossRef][Medline] [Order article via Infotrieve]
54. Mureebe L, Nelson PR, Yamamura S, Lawitts J, Kent KC. Activation of pp60c-src is necessary for human vascular smooth muscle cell migration. Surgery. 1997; 122: 138–144.[CrossRef][Medline] [Order article via Infotrieve]
55. Owens LV, Xu L, Marston WA, Yang X, Farber MA, Iacocca MV, Cance WG, Keagy BA. Overexpression of the focal adhesion kinase (p125FAK) in the vascular smooth muscle cells of intimal hyperplasia. J Vasc Surg. 2001; 34: 344–349.[CrossRef][Medline] [Order article via Infotrieve]
56. Gahtan V, Wang XJ, Ikeda M, Willis AI, Tuszynski GP, Sumpio BE. Thrombospondin-1 induces activation of focal adhesion kinase in vascular smooth muscle cells. J Vasc Surg. 1999; 29: 1031–1036.[CrossRef][Medline] [Order article via Infotrieve]
57. Yanagi H, Sasaguri Y, Sugama K, Morimatsu M, Nagase H. Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis. 1991; 91: 207–216.[CrossRef][Medline] [Order article via Infotrieve]
58. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994; 75: 539–545.
59. Paulhe F, Bogyo A, Chap H, Perret B, Racaud-Sultan C. Vascular smooth muscle cell spreading onto fibrinogen is regulated by calpains and phospholipase C. Biochem Biophys Res Commun. 2001; 288: 875–881.[CrossRef][Medline] [Order article via Infotrieve]
60. Miyamoto S, Teramoto H, Coso OA, Gutkind JS, Burbelo PD, Akiyama SK, Yamada KM. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. J Cell Biol. 1995; 131: 791–805.
61. Webb DJ, Parsons JT, Horwitz AF. Adhesion assembly, disassembly and turnover in migrating cells—over and over and over again. Nat Cell Biol. 2002; 4: E97–E100.[CrossRef][Medline] [Order article via Infotrieve]
62. Laukaitis CM, Webb DJ, Donais K, Horwitz AF. Differential dynamics of alpha 5 integrin, paxillin, and alpha-actinin during formation and disassembly of adhesions in migrating cells. J Cell Biol. 2001; 153: 1427–1440.
63. Manabe R, Kovalenko M, Webb DJ, Horwitz AR. GIT1 functions in a motile, multi-molecular signaling complex that regulates protrusive activity and cell migration. J Cell Sci. 2002; 115: 1497–1510.
64. Polte TR, Eichler GS, Wang N, Ingber DE. Extracellular matrix controls myosin light chain phosphorylation and cell contractility through modulation of cell shape and cytoskeletal prestress. Am J Physiol Cell Physiol. 2004; 286: C518–C528.
65. Gomes ER, Jani S, Gundersen GG. Nuclear movement regulated by Cdc42, MRCK, myosin, and actin flow establishes MTOC polarization in migrating cells. Cell. 2005; 121: 451–463.[CrossRef][Medline] [Order article via Infotrieve]
66. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, Froehlich JP, Crow MT, Lakatta EG, Rowinsky EK. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 1995; 95: 1869–1876.[Medline] [Order article via Infotrieve]
67. Kaverina I, Krylyshkina O, Small JV. Microtubule Targeting of substrate contacts promotes their relaxation and dissociation. J Cell Biol. 1999; 146: 1033–1044.
68. Galaria II, Nicholl SM, Roztocil E, Davies MG. Urokinase-induced smooth muscle cell migration requires PI3-K and Akt activation. J Surg Res. 2005; 127: 46–52.[CrossRef][Medline] [Order article via Infotrieve]
69. Scherberich A, Campos-Toimil M, Ronde P, Takeda K, Beretz A. Migration of human vascular smooth muscle cells involves serum-dependent repeated cytosolic calcium transients. J Cell Sci. 2000; 113 (pt 4): 653–662.[Abstract]
70. Kishi H, Bao J, Kohama K. Inhibitory effects of ML-9, wortmannin, and Y-27632 on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. J Biochem (Tokyo). 2000; 128: 719–722.
71. Nakayama M, Amano M, Katsumi A, Kaneko T, Kawabata S, Takefuji M, Kaibuchi K. Rho-kinase and myosin II activities are required for cell type and environment specific migration. Genes Cells. 2005; 10: 107–117.
72. Hobson JP, Rosenfeldt HM, Barak LS, Olivera A, Poulton S, Caron MG, Milstien S, Spiegel S. Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science. 2001; 291: 1800–1803.
73. Renault AD, Lehmann R. Follow the fatty brick road: lipid signaling in cell migration. Curr Opin Genet Dev. 2006; 16: 348–354.[CrossRef][Medline] [Order article via Infotrieve]
74. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000; 106: 951–961.[Medline] [Order article via Infotrieve]
75. Kluk MJ, Hla T. Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res. 2001; 89: 496–502.
76. Tanski W, Roztocil E, Davies MG. Sphingosine-1-phosphate induces G(alphai)-coupled, PI3K/ras-dependent smooth muscle cell migration. J Surg Res. 2002; 108: 98–106.[CrossRef][Medline] [Order article via Infotrieve]
77. Boguslawski G, Grogg JR, Welch Z, Ciechanowicz S, Sliva D, Kovala AT, McGlynn P, Brindley DN, Rhoades RA, English D. Migration of vascular smooth muscle cells induced by sphingosine 1-phosphate and related lipids: potential role in the angiogenic response. Exp Cell Res. 2002; 274: 264–274.[CrossRef][Medline] [Order article via Infotrieve]
78. Takuwa Y. Subtype-specific differential regulation of Rho family G proteins and cell migration by the Edg family sphingosine-1-phosphate receptors. Biochim Biophys Acta. 2002; 1582: 112–120.[Medline] [Order article via Infotrieve]
79. Usui S, Sugimoto N, Takuwa N, Sakagami S, Takata S, Kaneko S, Takuwa Y. Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5. J Biol Chem. 2004; 279: 12300–12311.
80. Waters C, Sambi B, Kong KC, Thompson D, Pitson SM, Pyne S, Pyne NJ. Sphingosine 1-phosphate and platelet-derived growth factor (PDGF) act via PDGF beta receptor-sphingosine 1-phosphate receptor complexes in airway smooth muscle cells. J Biol Chem. 2003; 278: 6282–6290.
81. Rosenfeldt HM, Hobson JP, Milstien S, Spiegel S. The sphingosine-1-phosphate receptor EDG-1 is essential for platelet-derived growth factor-induced cell motility. Biochem Soc Trans. 2001; 29: 836–839.[CrossRef][Medline] [Order article via Infotrieve]
82. Rosenfeldt HM, Hobson JP, Maceyka M, Olivera A, Nava VE, Milstien S, Spiegel S. EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration. FASEB J. 2001; 15: 2649–2659.
83. Waters CM, Long J, Gorshkova I, Fujiwara Y, Connell M, Belmonte KE, Tigyi G, Natarajan V, Pyne S, Pyne NJ. Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1-phosphate receptor-1. FASEB J. 2006; 20: 509–511.
84. Sakata Y, Xiang F, Chen Z, Kiriyama Y, Kamei CN, Simon DI, Chin MT. Transcription factor CHF1/Hey2 regulates neointimal formation in vivo and vascular smooth muscle proliferation and migration in vitro. Arterioscler Thromb Vasc Biol. 2004; 24: 2069–2074.
85. Ohtsu H, Mifune M, Frank GD, Saito S, Inagami T, Kim-Mitsuyama S, Takuwa Y, Sasaki T, Rothstein JD, Suzuki H, Nakashima H, Woolfolk EA, Motley ED, Eguchi S. Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol. 2005; 25: 1831–1836.
86. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol. 2006; 290: C661–C668.
87. Seasholtz TM, Majumdar M, Kaplan DD, Brown JH. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res. 1999; 84: 1186–1193.
88. Negoro N, Hoshiga M, Seto M, Kohbayashi E, Ii M, Fukui R, Shibata N, Nakakoji T, Nishiguchi F, Sasaki Y, Ishihara T, Ohsawa N. The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. Biochem Biophys Res Commun. 1999; 262: 211–215.[CrossRef][Medline] [Order article via Infotrieve]
89. Liu B, Itoh H, Louie O, Kubota K, Kent KC. The signaling protein Rho is necessary for vascular smooth muscle migration and survival but not for proliferation. Surgery. 2002; 132: 317–325.[CrossRef][Medline] [Order article via Infotrieve]
90. Somlyo AV. New roads leading to Ca2+ sensitization. Circ Res. 2002; 91: 83–84.
91. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci. 2001; 22: 32–39.[CrossRef][Medline] [Order article via Infotrieve]
92. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 1996; 271: 20246–20249.
93. Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F. Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J Cell Biol. 2000; 150: 797–806.
94. Sumi T, Matsumoto K, Takai Y, Nakamura T. Cofilin phosphorylation and actin cytoskeletal dynamics regulated by rho- and Cdc42-activated LIM-kinase 2. J Cell Biol. 1999; 147: 1519–1532.
95. Boengler K, Pipp F, Broich K, Fernandez B, Schaper W, Deindl E. Identification of differentially expressed genes like cofilin2 in growing collateral arteries. Biochem Biophys Res Commun. 2003; 300: 751–756.[CrossRef][Medline] [Order article via Infotrieve]
96. Dai YP, Bongalon S, Tian H, Parks SD, Mutafova-Yambolieva VN, Yamboliev IA. Upregulation of profilin, cofilin-2 and LIMK2 in cultured pulmonary artery smooth muscle cells and in pulmonary arteries of monocrotaline-treated rats. Vascul Pharmacol. 2006; 44: 275–282.[CrossRef][Medline] [Order article via Infotrieve]
97. Doanes AM, Irani K, Goldschmidt-Clermont PJ, Finkel T. A requirement for rac1 in the PDGF-stimulated migration of fibroblasts and vascular smooth cells. Biochem Mol Biol Int. 1998; 45: 279–287.[Medline] [Order article via Infotrieve]
98. Tien Y, Autieri M. Cytokine expression and AIF-1-mediated activation of Rac2 in vascular smooth muscle cells: a role for Rac2 in VSMC activation. Am J Physiol Cell Physiol. 2006; 292: C841–C849.[CrossRef][Medline] [Order article via Infotrieve]
99. Liu D, Hou J, Hu X, Wang X, Xiao Y, Mou Y, De LH. Neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation. Circ Res. 2006; 98: 480–489.
100. Weber DS, Taniyama Y, Rocic P, Seshiah PN, Dechert MA, Gerthoffer WT, Griendling KK. Phosphoinositide-dependent kinase 1 and p21-activated protein kinase mediate reactive oxygen species-dependent regulation of platelet-derived growth factor-induced smooth muscle cell migration. Circ Res. 2004; 94: 1219–1226.
101. Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1999; 1: 253–259.[CrossRef][Medline] [Order article via Infotrieve]
102. Wirth A, Schroeter M, Kock-Hauser C, Manser E, Chalovich JM, De Lanerolle P, Pfitzer G. Inhibition of contraction and myosin light chain phosphorylation in guinea-pig smooth muscle by p21-activated kinase 1. J Physiol. 2003; 549: 489–500.
103. Van Eyk JE, Arrell DK, Foster DB, Strauss JD, Heinonen TY, Furmaniak-Kazmierczak E, Cote GP, Mak AS. Different molecular mechanisms for Rho family GTPase-dependent, Ca2+-independent contraction of smooth muscle. J Biol Chem. 1998; 273: 23433–23439.
104. McFawn PK, Shen L, Vincent SG, Mak A, Van Eyk JE, Fisher JT. Calcium-independent contraction and sensitization of airway smooth muscle by p21-activated protein kinase. Am J Physiol Lung Cell Mol Physiol. 2003; 284: L863–L870.
105. Yamboliev IA, Gerthoffer WT. Modulatory role of ERK MAPK-caldesmon pathway in PDGF-stimulated migration of cultured pulmonary artery SMCs. Am J Physiol Cell Physiol. 2001; 280: C1680–C1688.
106. Kordowska J, Hetrick T, Adam LP, Wang CL. Phosphorylated l-caldesmon is involved in disassembly of actin stress fibers and postmitotic spreading. Exp Cell Res. 2006; 312: 95–110.[CrossRef][Medline] [Order article via Infotrieve]
107. Webb BA, Zhou S, Eves R, Shen L, Jia L, Mak AS. Phosphorylation of cortactin by p21-activated kinase. Arch Biochem Biophys. 2006; 456: 183–193.[CrossRef][Medline] [Order article via Infotrieve]
108. Wittmann T, Bokoch GM, Waterman-Storer CM. Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. J Biol Chem. 2004; 279: 6196–6203.
109. Ohtakara K, Inada H, Goto H, Taki W, Manser E, Lim L, Izawa I, Inagaki M. p21-activated kinase PAK phosphorylates desmin at sites different from those for Rho-associated kinase. Biochem Biophys Res Commun. 2000; 272: 712–716.[CrossRef][Medline] [Order article via Infotrieve]
110. Li QF, Spinelli AM, Wang R, Anfinogenova Y, Singer HA, Tang DD. Critical role of vimentin phosphorylation at Ser-56 by p21-activated kinase (PAK) in vimentin cytoskeleton signaling. J Biol Chem. 2006; 281: 34716–34724.
111. Dechert MA, Holder JM, Gerthoffer WT. p21-activated kinase 1 participates in tracheal smooth muscle cell migration by signaling to p38 Mapk. Am J Physiol Cell Physiol. 2001; 281: C123–C132.
112. Bokoch GM, Wang Y, Bohl BP, Sells MA, Quilliam LA, Knaus UG. Interaction of the Nck adapter protein with p21-activated kinase (PAK1). J Biol Chem. 1996; 271: 25746–25749.
113. Bagrodia S, Bailey D, Lenard Z, Hart M, Guan JL, Premont RT, Taylor SJ, Cerione RA. A tyrosine-phosphorylated protein that binds to an important regulatory region on the cool family of p21-activated kinase-binding proteins. J Biol Chem. 1999; 274: 22393–22400.
114. Turner CE, Brown MC, Perrotta JA, Riedy MC, Nikolopoulos SN, McDonald AR, Bagrodia S, Thomas S, Leventhal PS. Paxillin LD4 motif binds PAK and PIX through a novel 95-kD ankyrin repeat, ARF-GAP protein: a role in cytoskeletal remodeling. J Cell Biol. 1999; 145: 851–863.
115. Waltenberger J, Uecker A, Kroll J, Frank H, Mayr U, Bjorge JD, Fujita D, Gazit A, Hombach V, Levitzki A, Bohmer FD. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. Circ Res. 1999; 85: 12–22.
116. Yamboliev IA, Chen J, Gerthoffer WT. PI 3-kinases and Src kinases regulate spreading and migration of cultured VSMCs. Am J Physiol Cell Physiol. 2001; 281: C709–C718.
117. Pukac L, Huangpu J, Karnovsky MJ. Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration. Exp Cell Res. 1998; 242: 548–560.[CrossRef][Medline] [Order article via Infotrieve]
118. Higaki M, Sakaue H, Ogawa W, Kasuga M, Shimokado K. Phosphatidylinositol 3-kinase-independent signal transduction pathway for platelet-derived growth factor-induced chemotaxis. J Biol Chem. 1996; 271: 29342–29346.
119. Cospedal R, Abedi H, Zachary I. Platelet-derived growth factor-BB (PDGF-BB) regulation of migration and focal adhesion kinase phosphorylation in rabbit aortic vascular smooth muscle cells: roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinases. Cardiovasc Res. 1999; 41: 708–721.
120. Liu B, Itoh H, Louie O, Kubota K, Kent KC. The role of phospholipase C and phosphatidylinositol 3-kinase in vascular smooth muscle cell migration and proliferation. J Surg Res. 2004; 120: 256–265.[CrossRef][Medline] [Order article via Infotrieve]
121. Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, Law RE. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension. 1997; 29: 334–339.
122. Nelson PR, Yamamura S, Mureebe L, Itoh H, Kent KC. Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogen-activated protein kinase. J Vasc Surg. 1998; 27: 117–125.[CrossRef][Medline] [Order article via Infotrieve]
123. Wang XQ, Lindberg FP, Frazier WA. Integrin-associated protein stimulates alpha2beta1-dependent chemotaxis via Gi-mediated inhibition of adenylate cyclase and extracellular-regulated kinases. J Cell Biol. 1999; 147: 389–400.
124. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 1997; 137: 481–492.
125. Goldman J, Zhong L, Liu SQ. Negative regulation of vascular smooth muscle cell migration by blood shear stress. Am J Physiol Heart Circ Physiol. 2007; 292: H928–H938.
126. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci. 2004; 117: 4619–4628.
127. Cho A, Graves J, Reidy MA. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000; 20: 2527–2532.
128. Sharony R, Pintucci G, Saunders PC, Grossi EA, Baumann FG, Galloway AC, Mignatti P. Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and -2. Am J Physiol Heart Circ Physiol. 2006; 290: H1651–H1659.
129. Hedges JC, Dechert MA, Yamboliev IA, Martin JL, Hickey E, Weber LA, Gerthoffer WT. A role for p38(MAPK)/HSP27 pathway in smooth muscle cell migration. J Biol Chem. 1999; 274: 24211–24219.
130. Pichon S, Bryckaert M, Berrou E. Control of actin dynamics by p38 MAP kinase – Hsp27 distribution in the lamellipodium of smooth muscle cells. J Cell Sci. 2004; 117: 2569–2577.
131. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997; 15: 2169–2177.[CrossRef][Medline] [Order article via Infotrieve]
132. Wang Z, Castresana MR, Newman WH. Reactive oxygen species-sensitive p38 MAPK controls thrombin-induced migration of vascular smooth muscle cells. J Mol Cell Cardiol. 2004; 36: 49–56.[CrossRef][Medline] [Order article via Infotrieve]
133. Ju H, Nerurkar S, Sauermelch CF, Olzinski AR, Mirabile R, Zimmerman D, Lee JC, Adams J, Sisko J, Berova M, Willette RN. Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury. J Pharmacol Exp Ther. 2002; 301: 15–20.
134. Chen Q, Li W, Quan Z, Sumpio BE. Modulation of vascular smooth muscle cell alignment by cyclic strain is dependent on reactive oxygen species and P38 mitogen-activated protein kinase. J Vasc Surg. 2003; 37: 660–668.[CrossRef][Medline] [Order article via Infotrieve]
135. Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, Iwao H. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol. 2003; 23: 795–801.
136. Ioroi T, Yamamori M, Yagi K, Hirai M, Zhan Y, Kim S, Iwao H. Dominant negative c-Jun inhibits platelet-derived growth factor-directed migration by vascular smooth muscle cells. J Pharmacol Sci. 2003; 91: 145–148.[CrossRef][Medline] [Order article via Infotrieve]
137. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature. 2003; 424: 219–223.[CrossRef][Medline] [Order article via Infotrieve]
138. Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol. 2001; 155: 505–510.
139. Nikolopoulos SN, Turner CE. Integrin-linked kinase (ILK) binding to paxillin LD1 motif regulates ILK localization to focal adhesions. J Biol Chem. 2001; 276: 23499–23505.
140. Deng JT, Sutherland C, Brautigan DL, Eto M, Walsh MP. Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase. Biochem J. 2002; 367: 517–524.[CrossRef][Medline] [Order article via Infotrieve]
141. Muranyi A, MacDonald JA, Deng JT, Wilson DP, Haystead TA, Walsh MP, Erdodi F, Kiss E, Wu Y, Hartshorne DJ. Phosphorylation of the myosin phosphatase target subunit by integrin-linked kinase. Biochem J. 2002; 366: 211–216.[Medline] [Order article via Infotrieve]
142. Wilson DP, Sutherland C, Borman MA, Deng JT, MacDonald JA, Walsh MP. Integrin-linked kinase is responsible for Ca2+-independent myosin diphosphorylation and contraction of vascular smooth muscle. Biochem J. 2005; 392: 641–648.[CrossRef][Medline] [Order article via Infotrieve]
143. Friedrich EB, Clever YP, Wassmann S, Werner N, Bohm M, Nickenig G. Role of integrin-linked kinase in vascular smooth muscle cells: regulation by statins and angiotensin II. Biochem Biophys Res Commun. 2006; 349: 883–889.[CrossRef][Medline] [Order article via Infotrieve]
144. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004; 37: 449–471.[CrossRef][Medline] [Order article via Infotrieve]
145. Moon SK, Kim HM, Kim CH. PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NF-kappaB and AP-1 in vascular smooth muscle cells. Arch Biochem Biophys. 2004; 421: 267–276.[CrossRef][Medline] [Order article via Infotrieve]
146. Zhang L, Yu Q, He J, Zha X. Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines. Mol Cell Biochem. 2004; 262: 25–33.[CrossRef][Medline] [Order article via Infotrieve]
147. Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science. 2004; 303: 1179–1181.
148. Welch HC, Coadwell WJ, Stephens LR, Hawkins PT. Phosphoinositide 3-kinase-dependent activation of Rac. FEBS Lett. 2003; 546: 93–97.[CrossRef][Medline] [Order article via Infotrieve]
149. Huang J, Kontos CD. Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Arterioscler Thromb Vasc Biol. 2002; 22: 745–751.
150. Andres V, Gascon-Irun M, Pandolfi PP, Gonzalez-Navarro H. Atheroma development in apolipoprotein E-null mice is not affected by partial inactivation of PTEN. Front Biosci. 2006; 11: 2739–2745.[CrossRef][Medline] [Order article via Infotrieve]
151. Woods TC, Marks AR. Drug-eluting stents. Annu Rev Med. 2004; 55: 169–178.[CrossRef][Medline] [Order article via Infotrieve]
152. Seidel CL, Helgason T, Allen JC, Wilson C. Migratory abilities of different vascular cells from the tunica media of canine vessels. Am J Physiol. 1997; 272: C847–C852.[Medline] [Order article via Infotrieve]
153. Li S, Sims S, Jiao Y, Chow LH, Pickering JG. Evidence from a novel human cell clone that adult vascular smooth muscle cells can convert reversibly between noncontractile and contractile phenotypes. Circ Res. 1999; 85: 338–348.
154. Pauly RR, Bilato C, Sollott SJ, Monticone R, Kelly PT, Lakatta EG, Crow MT. Role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration. Circulation. 1995; 91: 1107–1115.
155. Fukui R, Amakawa M, Hoshiga M, Shibata N, Kohbayashi E, Seto M, Sasaki Y, Ueno T, Negoro N, Nakakoji T, Ii M, Nishiguchi F, Ishihara T, Ohsawa N. Increased migration in late G(1) phase in cultured smooth muscle cells. Am J Physiol Cell Physiol. 2000; 279: C999–C1007.
156. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996; 98: 2277–2283.[Medline] [Order article via Infotrieve]
157. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation. 2001; 103: 2967–2972.
158. Ishigami M, Swertfeger DK, Granholm NA, Hui DY. Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J Biol Chem. 1998; 273: 20156–20161.
159. Wu D, Doods H, Stassen JM. Inhibition of human pulmonary artery smooth muscle cell proliferation and migration by sabiporide, a new specific NHE-1 inhibitor. J Cardiovasc Pharmacol. 2006; 48: 34–40.[CrossRef][Medline] [Order article via Infotrieve]
160. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998; 83: 1097–1103.
161. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, Law RE. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol. 1999; 33: 798–806.[CrossRef][Medline] [Order article via Infotrieve]
162. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1-> S transition in vascular smooth muscle cells. J Biol Chem. 2000; 275: 22435–22441.
163. Hidaka Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis. 1992; 95: 87–94.[CrossRef][Medline] [Order article via Infotrieve]
164. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol. 1995; 76: 21A–28A.[CrossRef][Medline] [Order article via Infotrieve]
165. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res. 2005; 97: 1232–1235.
166. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994; 75: 41–54.
167. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995; 77: 863–868.
168. Mason DP, Kenagy RD, Hasenstab D, Bowen-Pope DF, Seifert RA, Coats S, Hawkins SM, Clowes AW. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res. 1999; 85: 1179–1185.
169. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science. 2001; 294: 1708–1712.
170. Zaman MH, Trapani LM, Sieminski AL, Mackellar D, Gong H, Kamm RD, Wells A, Lauffenburger DA, Matsudaira P. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc Natl Acad Sci U S A. 2006; 103: 10889–10894.
171. Dormann D, Weijer CJ. Imaging of cell migration. EMBO J. 2006; 25: 3480–3493.[CrossRef][Medline] [Order article via Infotrieve]
172. Keating TJ, Borisy GG. Speckle microscopy: when less is more. Curr Biol. 2000; 10: R22–R24.[CrossRef][Medline] [Order article via Infotrieve]
173. Giepmans BN, Adams SR, Ellisman MH, Tsien RY. The fluorescent toolbox for assessing protein location and function. Science. 2006; 312: 217–224.
174. Li S, Moon JJ, Miao H, Jin G, Chen BP, Yuan S, Hu Y, Usami S, Chien S. Signal transduction in matrix contraction and the migration of vascular smooth muscle cells in three-dimensional matrix. J Vasc Res. 2003; 40: 378–388.[CrossRef][Medline] [Order article via Infotrieve]
175. Even-Ram S, Yamada KM. Cell migration in 3D matrix. Curr Opin Cell Biol. 2005; 17: 524–532.[CrossRef][Medline] [Order article via Infotrieve]
176. Pollard TD, Blanchoin L, Mullins RD. Actin dynamics. J Cell Sci. 2001; 114: 3–4.
177. Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990; 137: 7–12.[Abstract]
178. Sato Y, Hamanaka R, Ono J, Kuwano M, Rifkin DB, Takaki R. The stimulatory effect of PDGF on vascular smooth muscle cell migration is mediated by the induction of endogenous basic FGF. Biochem Biophys Res Commun. 1991; 174: 1260–1266.[CrossRef][Medline] [Order article via Infotrieve]
179. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol. 1993; 122: 933–940.
180. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994; 93: 1266–1274.[Medline] [Order article via Infotrieve]
181. Nomoto A, Mutoh S, Hagihara H, Yamaguchi I. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis. 1988; 72: 213–219.[CrossRef][Medline] [Order article via Infotrieve]
182. Wang Z, Newman WH. Smooth muscle cell migration stimulated by interleukin 6 is associated with cytoskeletal reorganization. J Surg Res. 2003; 111: 261–266.[CrossRef][Medline] [Order article via Infotrieve]
183. Koyama N, Koshikawa T, Morisaki N, Saito Y, Yoshida S. Bifunctional effects of transforming growth factor-beta on migration of cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1990; 169: 725–729.[CrossRef][Medline] [Order article via Infotrieve]
184. Merwin JR, Newman W, Beall LD, Tucker A, Madri J. Vascular cells respond differentially to transforming growth factors beta 1 and beta 2 in vitro. Am J Pathol. 1991; 138: 37–51.[Abstract]
185. Jovinge S, Hultgardh-Nilsson A, Regnstrom J, Nilsson J. Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Arterioscler Thromb Vasc Biol. 1997; 17: 490–497.
186. Noda-Heiny H, Sobel BE. Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. Am J Physiol. 1995; 268: C1195–C1201.[Medline] [Order article via Infotrieve]
187. Stepanova V, Bobik A, Bibilashvily R, Belogurov A, Rybalkin I, Domogatsky S, Little PJ, Goncharova E, Tkachuk V. Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factor-like domain. FEBS Lett. 1997; 414: 471–474.[CrossRef][Medline] [Order article via Infotrieve]
188. Herbert JM, Lamarche I, Carmeliet P. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells. J Biol Chem. 1997; 272: 23585–23591.
189. Grosskreutz CL, nand-Apte B, Duplaa C, Quinn TP, Terman BI, Zetter B, D’Amore PA. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res. 1999; 58: 128–136.[CrossRef][Medline] [Order article via Infotrieve]
190. Ishida A, Murray J, Saito Y, Kanthou C, Benzakour O, Shibuya M, Wijelath ES. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol. 2001; 188: 359–368.[CrossRef][Medline] [Order article via Infotrieve]
191. Sibinga NE, Foster LC, Hsieh CM, Perrella MA, Lee WS, Endege WO, Sage EH, Lee ME, Haber E. Collagen VIII is expressed by vascular smooth muscle cells in response to vascular injury. Circ Res. 1997; 80: 532–541.
192. Adiguzel E, Hou G, Mulholland D, Hopfer U, Fukai N, Olsen B, Bendeck M. Migration and growth are attenuated in vascular smooth muscle cells with type VIII collagen-null alleles. Arterioscler Thromb Vasc Biol. 2006; 26: 56–61.
193. Savani RC, Wang C, Yang B, Zhang S, Kinsella MG, Wight TN, Stern R, Nance DM, Turley EA. Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM. J Clin Invest. 1995; 95: 1158–1168.[Medline] [Order article via Infotrieve]
194. Goueffic Y, Guilluy C, Guerin P, Patra P, Pacaud P, Loirand G. Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res. 2006; 72: 339–348.
195. Yabkowitz R, Mansfield PJ, Ryan US, Suchard SJ. Thrombospondin mediates migration and potentiates platelet-derived growth factor-dependent migration of calf pulmonary artery smooth muscle cells. J Cell Physiol. 1993; 157: 24–32.[CrossRef][Medline] [Order article via Infotrieve]
196. Brown SL, Lundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res. 1994; 28: 1815–1820.
197. Chaulet H, Desgranges C, Renault MA, Dupuch F, Ezan G, Peiretti F, Loirand G, Pacaud P, Gadeau AP. Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin. Circ Res. 2001; 89: 772–778.
198. Bell L, Madri JA. Effect of platelet factors on migration of cultured bovine aortic endothelial and smooth muscle cells. Circ Res. 1989; 65: 1057–1065.
199. Campbell M, Trimble ER. Modification of PI3K- and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII. Circ Res. 2005; 96: 197–206.
200. Corley KM, Taylor CJ, Lilly B. Hypoxia-inducible factor 1alpha modulates adhesion, migration, and FAK phosphorylation in vascular smooth muscle cells. J Cell Biochem. 2005; 96: 971–985.[CrossRef][Medline] [Order article via Infotrieve]
201. Kenagy RD, Clowes AW. Blockade of smooth muscle cell migration and proliferation in baboon aortic explants by interleukin-1beta and tumor necrosis factor-alpha is nitric oxide-dependent and nitric oxide-independent. J Vasc Res. 2000; 37: 381–389.[CrossRef][Medline] [Order article via Infotrieve]
202. Selzman CH, McIntyre RC Jr, Shames BD, Whitehill TA, Banerjee A, Harken AH. Interleukin-10 inhibits human vascular smooth muscle proliferation. J Mol Cell Cardiol. 1998; 30: 889–896.[CrossRef][Medline] [Order article via Infotrieve]
203. Tannenbaum JE, Waleh NS, Mauray F, Breuss J, Pytela R, Kramer RH, Clyman RI. Transforming growth factor beta 1 inhibits fetal lamb ductus arteriosus smooth muscle cell migration. Pediatr Res. 1995; 37: 561–570.[Medline] [Order article via Infotrieve]
204. Kang SK, Yi KS, Kwon NS, Park KH, Kim UH, Baek KJ, Im MJ. Alpha1B-adrenoceptor signaling and cell motility: GTPase function of Gh/transglutaminase 2 inhibits cell migration through interaction with cytoplasmic tail of integrin alpha subunits. J Biol Chem. 2004; 279: 36593–36600.
205. Yasunari K, Kohno M, Hasuma T, Horio T, Kano H, Yokokawa K, Minami M, Yoshikawa J. Dopamine as a novel antimigration and antiproliferative factor of vascular smooth muscle cells through dopamine D1-like receptors. Arterioscler Thromb Vasc Biol. 1997; 17: 3164–3173.
206. Johnson R, Webb JG, Newman WH, Wang Z. Regulation of human vascular smooth muscle cell migration by beta-adrenergic receptors. Am Surg. 2006; 72: 51–54.[Medline] [Order article via Infotrieve]
207. Thorgeirsson G, Robertson AL Jr, Cowan DH. Migration of human vascular endothelial and smooth muscle cells. Lab Invest. 1979; 41: 51–62.[Medline] [Order article via Infotrieve]
208. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, Liao JK. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res. 2002; 90: 1020–1027.
209. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest. 1995; 96: 141–149.[Medline] [Order article via Infotrieve]
210. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 1996; 78: 225–230.
211. Mizutani M, Asano M, Roy S, Nakajima T, Soma M, Yamashita K, Okuda Y. Omega-3 polyunsaturated fatty acids inhibit migration of human vascular smooth muscle cells in vitro. Life Sci. 1997; 61: L269–L274.
212. Rosenkranz S, Knirel D, Dietrich H, Flesch M, Erdmann E, Bohm M. Inhibition of the PDGF receptor by red wine flavonoids provides a molecular explanation for the "French paradox". FASEB J. 2002; 16: 1958–1960.
This article has been cited by other articles:
 |
|
 |
|
  D. D. Tang p130 Crk-Associated Substrate (CAS) in Vascular Smooth Muscle Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2009; 14(2): 89 - 98. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Wang, J. Zheng, X. Bai, B. Liu, C.-j. Liu, Q. Xu, Y. Zhu, N. Wang, W. Kong, and X. Wang ADAMTS-7 Mediates Vascular Smooth Muscle Cell Migration and Neointima Formation in Balloon-Injured Rat Arteries Circ. Res., March 13, 2009; 104(5): 688 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Suzuki, K. Kimura, H. Shirai, K. Eguchi, S. Higuchi, A. Hinoki, K. Ishimaru, E. Brailoiu, D. N. Dhanasekaran, L. N. Stemmle, et al. Endothelial Nitric Oxide Synthase Inhibits G12/13 and Rho-Kinase Activated by the Angiotensin II Type-1 Receptor: Implication in Vascular Migration Arterioscler. Thromb. Vasc. Biol., February 1, 2009; 29(2): 217 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rodriguez-Menocal, M. St-Pierre, Y. Wei, S. Khan, D. Mateu, M. Calfa, A. A. Rahnemai-Azar, G. Striker, S. M. Pham, and R. I. Vazquez-Padron The origin of post-injury neointimal cells in the rat balloon injury model Cardiovasc Res, January 1, 2009; 81(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tada, J. Nawata, H. Wang, N. Onoue, D. Zhulanqiqige, K. Ito, K. Sugimura, Y. Fukumoto, and H. Shimokawa Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension Cardiovasc Res, December 1, 2008; 80(3): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Meng, D.-D. Lv, and J. Fang Insulin-like growth factor-I induces reactive oxygen species production and cell migration through Nox4 and Rac1 in vascular smooth muscle cells Cardiovasc Res, November 1, 2008; 80(2): 299 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Yokoyama, S. Minamisawa, H. Quan, T. Akaike, S. Suzuki, M. Jin, Q. Jiao, M. Watanabe, K. Otsu, S. Iwasaki, et al. Prostaglandin E2-activated Epac Promotes Neointimal Formation of the Rat Ductus Arteriosus by a Process Distinct from That of cAMP-dependent Protein Kinase A J. Biol. Chem., October 17, 2008; 283(42): 28702 - 28709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Fuller and D. J. Benos Putting the brakes on vascular smooth muscle cell migration Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H1987 - H1988. [Full Text] [PDF]
|
|
|
|
|
|
A. San Martin, M. Y. Lee, H. C. Williams, K. Mizuno, B. Lassegue, and K. K. Griendling Dual Regulation of Cofilin Activity by LIM Kinase and Slingshot-1L Phosphatase Controls Platelet-Derived Growth Factor-Induced Migration of Human Aortic Smooth Muscle Cells Circ. Res., February 29, 2008; 102(4): 432 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hayashi, O. Aharonovitz, R. T. Alexander, N. Touret, W. Furuya, J. Orlowski, and S. Grinstein Na+/H+ exchange and pH regulation in the control of neutrophil chemokinesis and chemotaxis Am J Physiol Cell Physiol, February 1, 2008; 294(2): C526 - C534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Gerthoffer Migration of Airway Smooth Muscle Cells Proceedings of the ATS, January 1, 2008; 5(1): 97 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zeidan, B. Paylor, K. J. Steinhoff, S. Javadov, V. Rajapurohitam, S. Chakrabarti, and M. Karmazyn Actin Cytoskeleton Dynamics Promotes Leptin-Induced Vascular Smooth Muscle Hypertrophy via RhoA/ROCK- and Phosphatidylinositol 3-Kinase/Protein Kinase B-Dependent Pathways J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1110 - 1116. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||